Rx pediculicide
This article was originally published in The Tan Sheet
Executive Summary
Summers Laboratories is actively enrolling patients in a Phase III clinical trial for its patented lice asphyxiator product, tentatively named Lice Choker, the company announces April 24. An NDA for sale of the product as an Rx drug will be filed in the fourth quarter of 2006. The product contains "a simple mixture of ingredients currently used in other dermatological medications and cosmetics" and will suffocate lice more successfully than olive oil and petroleum jelly, Summers maintains. According to studies, two 10-minute applications of the product one week apart effectively kill all lice, the company states, with one study showing a 100% effective kill rate. A recent article in the Journal of the American Academy of Dermatology said asphyxiating treatments should be further researched, given the increasing resistance of lice to OTC pyrethroid-based formulas (1"The Tan Sheet" April 17, 2006, p. 13)...
You may also be interested in...
Lice “Smothering” Agents Should Be Explored, Researchers Assert
Further research on topical agents that can asphyxiate lice should be conducted to enhance current treatment methods, according to a commentary published in the April issue of the Journal of the American Academy of Dermatology
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.